If FLASH dose rates have the potential to reduce TGF-β induction not only in normal tissues compared to CONV dose rates but also within the tumor microenvironment (TME), cancer cells would become more radiosensitive and tumor control could be improved (Figure 1). Here, TGFB1 is linked to neoplasm.